Libtayo Cleared for Frontline Use in Advanced NSCLC With High PD-L1 Expression
The approval is based on data from the randomized, open-label phase 3 EMPOWER-Lung1 trial.
Non-Small Cell Lung Cancer
Sotorasib Under Review for KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC
The Food and Drug Administration has placed sotorasib under priority review for patients with KRAS G12C-mutated locally advanced or metastatic NSCLC.
Proteasome Inhibition May Increase Alectinib Efficacy in ALK/TP53-Mutated NSCLC
Investigators studied genetic alterations related to ALK-TKI resistance in NSCLC and explored strategies to overcome resistance in preclinical models.
Combined Modalities Improve Survival in Stage III Inoperable NSCLC
This study tested the efficacy of singular and combined treatment modalities on survival in patients with inoperable, locally advanced non-small cell lung cancer (≥70 years).
